Immunology Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Trends Immunol. 2011 Jun;32(6):287-94. doi: 10.1016/j.it.2011.03.006. Epub 2011 Apr 29.
B cells play a pathogenic role as antigen-presenting cells and autoantibody secretors in the lead up to T cell-mediated autoimmune destruction of insulin-producing β cells in type 1 diabetes (T1D). This has led to significant interest in the use of B cell depletion therapies as a treatment for T1D. In this review, we compare results from five recent studies that used distinct B cell-depleting agents and protocols to successfully prevent and even reverse T1D in the non-obese diabetic (NOD) mouse model. We discuss how information gained from animal studies could be used to improve on the positive outcomes of a completed phase II clinical trial of the B cell-depleting drug rituximab in humans with recent-onset T1D.
B 细胞在导致 1 型糖尿病（T1D）的 T 细胞介导的胰岛β细胞自身免疫破坏的过程中，作为抗原呈递细胞和自身抗体分泌细胞，起着致病作用。这导致人们对使用 B 细胞耗竭疗法作为 T1D 的治疗方法产生了浓厚的兴趣。在这篇综述中，我们比较了最近五项使用不同 B 细胞耗竭剂和方案成功预防甚至逆转非肥胖型糖尿病（NOD）小鼠模型 T1D 的研究结果。我们讨论了如何利用从动物研究中获得的信息来改善针对近期发生 T1D 的人类使用 B 细胞耗竭药物利妥昔单抗的 II 期临床试验的阳性结果。
